The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165
Open accessAbstract
Small molecule JAK inhibitors have emerged as a major therapeutic advancement in treating autoimmune diseases. The discovery of isoform selective JAK inhibitors that traditionally target the catalytically active site of this kinase family has been a formidable challenge. Our strategy to achieve high selectivity for TYK2 relies on targeting the TYK2 pseudokinase (JH2) domain. Herein we report the late stage optimization efforts including a structure-guided design and water displacement strategy that led to the discovery of BMS-986165 ( 11 ) as a high affinity JH2 ligand and potent allosteric inhibitor of TYK2. In addition to unprecedented JAK isoform and kinome selectivity, 11 shows excellent pharmacokinetic properties with minimal profiling liabilities and is efficacious in several murine models of autoimmune disease. On the basis of these findings, 11 appears differentiated from all other reported JAK inhibitors and has been advanced as the first pseudokinase-directed therapeutic in clinical development as an oral treatment for autoimmune diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
Zheng, Y., Danilenko, D. M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J., & Ouyang, W. (2007) · Nature · doi:10.1038/nature05505 · Cited by 1,862
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
Sandborn, W. J., Su, C., Sands, B. E., D’Haens, G. R., Vermeire, S., Schreiber, S., Danese, S., Feagan, B. G., Reinisch, W., Niezychowski, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606910 · Cited by 1,770
Profound Methyl Effects in Drug Discovery and a Call for New CH Methylation Reactions
Schönherr, H., & Cernak, T. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201303207 · Cited by 1,094
Talele, T. T. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00472 · Cited by 1,023
Jak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesis
Neubauer, H., Cumano, A., Müller, M., Wu, H., Huffstadt, U., & Pfeffer, K. (1998) · Cell · doi:10.1016/s0092-8674(00)81168-x · Cited by 914
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Schwartz, D. M., Bonelli, M., Gadina, M., & O'Shea, J. J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.167 · Cited by 648
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Genovese, M. C., Kremer, J., Zamani, O., Ludivico, C., Krogulec, M., Xie, L., Beattie, S. D., Koch, A. E., Cardillo, T. E., Rooney, T. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507247 · Cited by 627
Clark, J. D., Flanagan, M. E., & Telliez, J.-B. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401490p · Cited by 601
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
Gladman, D., Rigby, W., Azevedo, V. F., Behrens, F., Blanco, R., Kaszuba, A., Kudlacz, E., Wang, C., Menon, S., Hendrikx, T., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615977 · Cited by 510
Ritchie, T. J., Macdonald, S. J. F., Young, R. J., & Pickett, S. D. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2010.11.014 · Cited by 442
Vermeire, S., Schreiber, S., Petryka, R., Kuehbacher, T., Hebuterne, X., Roblin, X., Klopocka, M., Goldis, A., Wisniewska-Jarosinska, M., Baranovsky, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32537-5 · Cited by 439
Genovese, M. C., Fleischmann, R., Combe, B., Hall, S., Rubbert-Roth, A., Zhang, Y., Zhou, Y., Mohamed, M.-E. F., Meerwein, S., & Pangan, A. L. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31116-4 · Cited by 422
Self-citationPhase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
Papp, K., Gordon, K., Thaçi, D., Morita, A., Gooderham, M., Foley, P., Girgis, I. G., Kundu, S., & Banerjee, S. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1806382 · Cited by 420
Bachelez, H., van de Kerkhof, P. C. M., Strohal, R., Kubanov, A., Valenzuela, F., Lee, J.-H., Yakusevich, V., Chimenti, S., Papacharalambous, J., Proulx, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62113-9 · Cited by 410
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
Parmentier, J. M., Voss, J., Graff, C., Schwartz, A., Argiriadi, M., Friedman, M., Camp, H. S., Padley, R. J., George, J. S., Hyland, D., et al. (2018) · BMC Rheumatology · doi:10.1186/s41927-018-0031-x · Cited by 390
Papp, K. A., Menter, M. A., Abe, M., Elewski, B., Feldman, S. R., Gottlieb, A. B., Langley, R., Luger, T., Thaci, D., Buonanno, M., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14018 · Cited by 327
(1990) · PubMed · Cited by 322
Wollenhaupt, J., Silverfield, J., Lee, E. B., Curtis, J. R., Wood, S. P., Soma, K., Nduaka, C. I., Benda, B., Gruben, D., Nakamura, H., et al. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130683 · Cited by 301
Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity
Dendrou, C. A., Cortes, A., Shipman, L., Evans, H. G., Attfield, K. E., Jostins, L., Barber, T., Kaur, G., Kuttikkatte, S. B., Leach, O. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1974 · Cited by 264
Papp, K. A., Menter, M. A., Raman, M., Disch, D., Schlichting, D. E., Gaich, C., Macias, W., Zhang, X., & Janes, J. M. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14403 · Cited by 263
Michel, J., Tirado-Rives, J., & Jorgensen, W. L. (2009) · Journal of the American Chemical Society · doi:10.1021/ja906058w · Cited by 256
Westhovens, R., Taylor, P. C., Alten, R., Pavlova, D., Enríquez-Sosa, F., Mazur, M., Greenwald, M., Van der Aa, A., Vanhoutte, F., Tasset, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210104 · Cited by 236
Lupardus, P. J., Ultsch, M., Wallweber, H., Bir Kohli, P., Johnson, A. R., & Eigenbrot, C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401180111 · Cited by 229
Kavanaugh, A., Kremer, J., Ponce, L., Cseuz, R., Reshetko, O. V., Stanislavchuk, M., Greenwald, M., Van der Aa, A., Vanhoutte, F., Tasset, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210105 · Cited by 229
The regulation of JAKs in cytokine signaling and its breakdown in disease
Hammarén, H. M., Virtanen, A. T., Raivola, J., & Silvennoinen, O. (2019) · Cytokine · doi:10.1016/j.cyto.2018.03.041 · Cited by 217
Fensome, A., Ambler, C. M., Arnold, E., Banker, M. E., Brown, M. F., Chrencik, J., Clark, J. D., Dowty, M. E., Efremov, I. V., Flick, A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00917 · Cited by 178
Self-citationThe Roles of Water in the Protein Matrix: A Largely Untapped Resource for Drug Discovery
Spyrakis, F., Ahmed, M. H., Bayden, A. S., Cozzini, P., Mozzarelli, A., & Kellogg, G. E. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00057 · Cited by 169
Vazquez, M. L., Kaila, N., Strohbach, J. W., Trzupek, J. D., Brown, M. F., Flanagan, M. E., Mitton-Fry, M. J., Johnson, T. A., TenBrink, R. E., Arnold, E. P., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01598 · Cited by 169
Self-citationPF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor
Xu, H., Jesson, M. I., Seneviratne, U. I., Lin, T. H., Sharif, M. N., Xue, L., Nguyen, C., Everley, R. A., Trujillo, J. I., Johnson, D. S., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00188 · Cited by 163
Deisseroth, A., Kaminskas, E., Grillo, J. A., Chen, W., Saber, H., Lu, H., Rothmann, M. D., Brar, S. S., Wang, J., Garnett, C. E., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0653 · Cited by 149
The Janus kinase family of protein tyrosine kinases and their role in signaling
Yeh, T. C., & Pellegrini, S. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050392 · Cited by 145
Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634
Menet, C. J., Fletcher, S. R., Lommen, G. V., Geney, R., Blanc, J., Smits, K., Jouannigot, N., Deprez, P., van der Aar, E. M., Clément-Lacroix, P., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501262q · Cited by 131
Tokarski, J. S., Zupa-Fernandez, A., Tredup, J. A., Pike, K. M., Chang, C. Y., Xie, D., Cheng, L., Pedicord, D. L., Muckelbauer, J. K., Johnson, S. R., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.619502 · Cited by 129
Self-citationATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation
Hammarén, H. M., Ungureanu, D., Grisouard, J., Skoda, R. C., Hubbard, S. R., & Silvennoinen, O. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423201112 · Cited by 122
Min, X., Ungureanu, D., Maxwell, S. S., Hammarén, H. M., Thibault, S., Hillert, E., Ayres, M., Greenfield, B., Eksterowicz, J. E., Gabel, C., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.672048 · Cited by 116
Accounting for water molecules in drug design
Wong, S., & Lightstone, F. C. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.534452 · Cited by 115
Moslin, R. M., Zhang, Y., Wrobleski, S. T., Lin, S., Mertzman, M., Spergel, S. H., Tokarski, J. S., Strnad, J., Gillooly, K. M., McIntyre, K. W., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00443 · Cited by 105
Self-citationJAK Kinases in Health and Disease: An Update
Laurence, A. D. J., Pesu, M., Silvennoinen, O., & O’Shea, J. J. (2012) · The Open Rheumatology Journal · doi:10.2174/1874312901206010232 · Cited by 104
Banfield, C. R., Scaramozza, M., Zhang, W., Kieras, E., Page, K. M., Fensome, A., Vincent, M. S., Dowty, M. E., Goteti, K., Winkle, P. J., et al. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1046 · Cited by 98
FDA approves tofacitinib for rheumatoid arthritis
Traynor, K. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/news120088 · Cited by 97
Genovese, M. C., Greenwald, M., Codding, C. E., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40054 · Cited by 92
Asahina, A., Etoh, T., Igarashi, A., Imafuku, S., Saeki, H., Shibasaki, Y., Tomochika, Y., Toyoizumi, S., Nagaoka, M., Ohtsuki, M., et al. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13258 · Cited by 85
Vanhoutte, F. P., Mazur, M., Voloshyn, O. I., Stanislavchuk, M., der Aa, A. V., Namour, F., Galien, R., Meuleners, L., & Klooster, G. A. E. V. '. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40186 · Cited by 83
He, Y., Wong, A. Y. S., Chan, E. W., Lau, W. C. Y., Man, K. K. C., Chui, C. S. L., Worsley, A. J., & Wong, I. C. K. (2013) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-14-298 · Cited by 82
Krimmer, S. G., Cramer, J., Betz, M., Fridh, V., Karlsson, R., Heine, A., & Klebe, G. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00998 · Cited by 82
Water, water, everywhere… It’s time to stop and think.
Bodnarchuk, M. S. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.05.009 · Cited by 81
Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances
Bryan, M. C., & Rajapaksa, N. S. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00667 · Cited by 77
Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018)
He, X., Chen, X., Zhang, H., Xie, T., & Ye, X. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1567713 · Cited by 76
Yang, Y., Lightstone, F. C., & Wong, S. E. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.749853 · Cited by 65
Tofacitinib for the treatment of rheumatoid arthritis
Zerbini, C. A. F., & Lomonte, A. B. V. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.12.19 · Cited by 63
Moslin, R. M., Gardner, D., Santella, J. B., Zhang, Y., Duncia, J. V., Liu, C., Lin, J., Tokarski, J. S., Strnad, J., Pedicord, D. L., et al. (2016) · MedChemComm · doi:10.1039/c6md00560h · Cited by 57
Self-citationLernia, V. G. D., & Bardazzi, F. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s82599 · Cited by 46
Halford, B. A. (2016) · C&EN Global Enterprise · doi:10.1021/cen-09427-cover · Cited by 42
Qin, B., Sun, C., Liu, Y., Shen, J., Ye, R., Zhu, J. Y., Duan, X., & Zeng, H. (2011) · Organic Letters · doi:10.1021/ol200538d · Cited by 37
Cited by
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Ghoreschi, K., Balato, A., Enerbäck, C., & Sabat, R. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00184-7 · Cited by 668
Deuterium in drug discovery: progress, opportunities and challenges
Di Martino, R. M. C., Maxwell, B. D., & Pirali, T. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00703-8 · Cited by 539
A Comprehensive Overview of Globally Approved JAK Inhibitors
Shawky, A. M., Almalki, F. A., Abdalla, A. N., Abdelazeem, A. H., & Gouda, A. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051001 · Cited by 349
hERG toxicity assessment: Useful guidelines for drug design
Garrido, A., Lepailleur, A., Mignani, S. M., Dallemagne, P., & Rochais, C. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112290 · Cited by 344
Metadata
- Authors
- Wrobleski, S. T., Moslin, R., Lin, S., Zhang, Y., Spergel, S., Kempson, J., Tokarski, J. S., Strnad, J., Zupa-Fernandez, A., Cheng, L., Shuster, D., Gillooly, K., Yang, X., Heimrich, E., McIntyre, K. W., Chaudhry, C., Khan, J., Ruzanov, M., Tredup, J., Mulligan, D., Xie, D., Sun, H., Huang, C., D’Arienzo, C., Aranibar, N., Chiney, M., Chimalakonda, A., Pitts, W. J., Lombardo, L., Carter, P. H., Burke, J. R., & Weinstein, D. S.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-07-18
- Volume
- 62
- Issue
- 20
- Pages
- 8973-8995
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2956179332
- Cited by
- 382
- References
- 55
- FWCI
- 11.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.